Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer

Phase 1

Completed

Conditions: Esophageal Cancer
Gastric Cancer
Liver Cancer

First Posted Date: 2007-09-28

Last Posted Date: 2013-06-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00537121

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bupropion in Helping Adults Stop Smoking

Phase 2

Completed

Conditions: Bladder Cancer
Cervical Cancer
Esophageal Cancer
Gastric Cancer
Head and Neck Cancer
Kidney Cancer
Leukemia
Liver Cancer
Lung Cancer
Pancreatic Cancer

Interventions: Drug: bupropion hydrochloride
Other: placebo

First Posted Date: 2007-09-24

Last Posted Date: 2017-05-30

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 95

Registration Number: NCT00534001

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

Not Applicable

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: donor lymphocytes

First Posted Date: 2007-09-24

Last Posted Date: 2020-08-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 39

Registration Number: NCT00534118

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat

Not Applicable

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: porfimer sodium
Drug: Photdynamic Therapy (PDT)

First Posted Date: 2007-09-17

Last Posted Date: 2014-07-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00530088

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: HPPH
Procedure: endoscopic procedure

First Posted Date: 2007-09-12

Last Posted Date: 2014-06-10

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 6

Registration Number: NCT00528775

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Dietary Supplement: selenomethionine
Drug: carboplatin
Drug: paclitaxel
Other: laboratory biomarker analysis
Radiation: radiation therapy

First Posted Date: 2007-09-10

Last Posted Date: 2017-11-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00526890

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: HPPH

First Posted Date: 2007-09-10

Last Posted Date: 2023-08-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 17

Registration Number: NCT00526461

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

Phase 1

Terminated

Conditions: Gastric Cancer
Esophageal Cancer

Interventions: Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: sunitinib malate
Other: flow cytometry
Other: pharmacological study

First Posted Date: 2007-09-03

Last Posted Date: 2016-06-21

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00524186

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Dietary Supplement: calcitriol
Drug: dexamethasone
Genetic: protein expression analysis
Other: laboratory biomarker analysis

First Posted Date: 2007-09-03

Last Posted Date: 2017-11-20

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00524589

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: bortezomib
Drug: pegylated liposomal doxorubicin hydrochloride
Drug: thalidomide

First Posted Date: 2007-09-03

Last Posted Date: 2017-02-23

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 46

Registration Number: NCT00523848

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy